Adenovirus Based Virotherapy Market size is anticipated to reach USD 27 billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of adenovirus based virotherapy was over USD 13 billion. The development and growth of the market is fueled by several factors, including ongoing clinical trials, regulatory approvals, and the commercialization of virotherapies. Positive results from clinical trials demonstrating the safety and efficacy of adenovirus-based virotherapy in treating certain types of cancer significantly drive market growth. Successful clinical outcomes contribute to regulatory approvals and increased industry interest. Along with these, escalating research & development concerned with adenovirus and surging demand for vector-based therapies are also projected to drive market growth in the coming years. Furthermore, rising government investments to spread awareness about early cancer detection are expected to provide ample growth opportunities to the market in the near future.
Adenovirus-based virotherapy involves the use of adenoviruses, which are common viruses that can cause respiratory and other infections in humans, as vectors to deliver therapeutic genes into cancer cells. These viruses are modified to selectively replicate in and destroy cancer cells while sparing normal, healthy cells. Obtaining regulatory approvals from agencies such as the FDA or EMA for adenovirus-based virotherapies is a critical factor for market growth. Regulatory clearance enables companies to bring their products to market and increases confidence among healthcare professionals and patients.
Growth Drivers
Challenges
Base Year |
2023 |
Forecast Year |
2024-2036 |
CAGR |
~6% |
Base Year Market Size (2023) |
~ USD 13 Billion |
Forecast Year Market Size (2036) |
~ USD 27 Billion |
Regional Scope |
|
Type (Oncolytic Adenoviruses, Gene Therapy Vectors)
The oncolytic adenoviruses segment in the adenovirus based virotherapy market is estimated to gain the largest revenue share of 60% in the year 2036. Oncolytic adenoviruses represent a cutting-edge approach in cancer therapy, leveraging the inherent ability of adenoviruses to infect and destroy cancer cells selectively. Several key drivers influence the growth of the oncolytic adenoviruses segment. One of the primary drivers propelling the growth of oncolytic adenoviruses is the relentless pursuit of advancements in virotherapy research. The increase in research investments underscores the commitment of the scientific community to explore and harness the potential of oncolytic adenoviruses in cancer treatment. Investments in oncolytic virotherapy research have witnessed an annual increase of 30% over the past five years, totaling USD 1.5 billion in the year 2022. Researchers are delving deep into understanding the intricate interactions between oncolytic adenoviruses and cancer cells. This includes refining the genetic modifications of adenoviruses to enhance tumor specificity and optimizing delivery mechanisms to improve their reach within tumor masses. Breakthroughs in virotherapy research are contributing to the development of safer, more potent oncolytic adenoviruses, driving the segment's growth.
End User (Hospitals, Research Institutes, Biopharmaceutical)
Adenovirus based virotherapy market from the hospitals segment is expected to garner a significant share in the year 2036. The hospitals segment plays a pivotal role in the growth and adoption of Adenovirus Based Virotherapy, serving as the primary point of access for patients seeking advanced cancer treatments. Several key drivers contribute to the growth of this segment. A significant growth driver for the hospitals segment is the escalating incidence of cancer, reflected in increase in hospital admissions. The burden of cancer has surged globally, necessitating advanced and targeted treatment modalities like Adenovirus Based Virotherapy. Hospitals, as comprehensive healthcare hubs, witness a steady influx of cancer patients seeking diagnosis, treatment, and specialized care. The rising demand for advanced therapies positions Adenovirus Based Virotherapy as a crucial component in hospitals' oncology services, fostering growth in the segment. Hospitals that comply with regulatory standards and achieve accreditation for virotherapy services demonstrate a commitment to patient safety and quality care. Accreditation fosters trust among patients, referring physicians, and regulatory bodies, positioning the hospital as a reliable provider of Adenovirus Based Virotherapy and supporting sustained growth in the segment.
Type |
|
End User |
|
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?